In Brief
HIV-1 vaccine elicitation of antibodies against neutralization-resistant (Tier-2) viruses is rare. Bradley et al. demonstrate induction of antibodies that can neutralize a vaccine-matched Tier-2 virus in a rhesus macaque immunized with HIV trimers isolated from a HIV-1-infected individual. Structural analysis revealed the mechanism of restricted neutralization breadth.
Accession Numbers 5F6H 5F6I 5F6J
INTRODUCTION
The HIV-1 envelope protein (Env) is the primary target of neutralizing antibodies (nAbs) (Wyatt and Sodroski, 1998; Zhou et al., 2007) . One major obstacle to developing an effective HIV-1 vaccine is finding an immunogen that can elicit broadly nAbs (bnAbs) with the capacity to overcome variability of the virus and to retain neutralizing activity for most circulating HIV-1 strains (Burton et al., 2012; Mascola and Haynes, 2013) .
Between 3 and 12 months after HIV-1 transmission, most infected individuals develop autologous, strain-specific nAbs to the transmitted/founder (TF) virus and TF variants (Ariyoshi et al., 1992; Richman et al., 2003; Wei et al., 2003) . The autologous nAb response drives viral escape and stimulates additional specificities of nAbs that neutralize escape viruses (Richman et al., 2003; Wei et al., 2003) . This antibody virus co-evolution persists throughout infection, and in 20% of individuals, it leads, after years of infection, to development of high levels of bnAbs (Doria-Rose et al., 2010; Gray et al., 2011; Liao et al., 2013a; Tomaras et al., 2011; Walker et al., 2011) .
Two recent studies mapped the ontogeny of bnAbs and TF viruses from the time of transmission to bnAb development and showed that bnAbs arise from autologous nAb B cell clonal lineages but that only a small number of the autologous nAb lineages ultimately evolve to neutralization breadth (Doria-Rose et al., 2014; Liao et al., 2013a) . Identification of immunogens that can induce nAbs against autologous, neutralization-resistant (Tier-2) viruses is a major challenge for HIV vaccine design, and examples of vaccine-matched, Tier-2 nAb responses elicited by vaccination in primates are few (Sanders et al., 2015; Willey et al., 2003) . Moreover, no vaccine-induced Tier-2 nAbs have yet been isolated and characterized, nor have structures of their Env complexes been determined.
CAP206 is an HIV-infected African individual who later developed gp41-targeted bnAbs (Gray et al., 2009a; Morris et al., 2011) . As a critical first step in HIV vaccine design, we sought to map the autologous nAb response and to elicit Tier-2 nAbs that mimicked this early autologous nAb response by immunization with Env proteins isolated over the course of infection. We report here that immunization of rhesus macaques with HIV-1 TF variants from CAP206 induced strainspecific nAbs to vaccine-matched Tier-2 autologous viruses in three of six animals. After only two immunizations, one macaque had a high-titer nAb response that targeted the CD4-binding site (bs) and mimicked the autologous nAb response observed in CAP206. We isolated a vaccine-induced nAb clonal lineage (DH427) that potently neutralized the Tier-2 CAP206 6-month virus and recapitulated the observed plasma neutralization response. A crystal structure of DH427 in complex with HIV Env showed that DH427 bound close to the CD4bs but also interacted with variable regions in the HIV Env (loop E and V5-loop) , explaining the restricted neutralization breadth and the failure of DH427 to evolve to heterologous neutralization.
RESULTS

Immunization of Rhesus Macaques Elicits Tier-2 Autologous Neutralization
We tracked the evolution of the CAP206 env gene from the TF virus until 39 months after transmission ( Figure 1A) . We selected the CAP206 TF and six additional representative mutant env genes from 2-, 6-, 12-, 21-, 24-, and 30-month time points and produced them as recombinant gp140 oligomers that were predominately trimers ( Figure S1A ). The antigenic and functional epitopes expressed on each of the recombinant CAP206 Envs were determined by SPR assays ( Figure S1B ). All Envs bound to CD4 and mAb A32, which binds well to uncleaved trimers, and the magnitude of CD4 binding increased in Envs isolated from later CAP206 time points ( Figure S1B ). The seven Envs showed binding to a panel of nAbs and bound to 17b, an antibody that binds to the CD4-induced conformation of Env, in the absence of CD4 ( Figure S2 ). Some Envs lacked binding of bnAbs that target the CD4bs, and others only reacted weakly, indicating disruption of canonical CD4bs bnAb epitopes in the CAP206 Envs.
We immunized six rhesus macaques with a cocktail of all seven CAP206 recombinant gp140 oligomers and collected plasma and PBMCs before the first immunization and 2 weeks after each subsequent immunization ( Figure 1B ). We tested plasma from Env-immunized animals for the presence of anti-HIV neutralizing activity using the TZM-bl pseudovirus assay. Plasmas collected before the first immunization (week 0) and 2 weeks after the last immunization (week 38) were tested for neutralization of heterologous, neutralizationsensitive (Tier-1) isolates MN (clade B) and MW965 (clade C) and of autologous, Tier-2, vaccine-matched isolates of the seven CAP206 Envs ( Figures 1C and S3A ). We observed potent neutralization titers against the Tier-1 MN and MW965 viruses in all animals. Low levels of neutralizing activity against Tier-2 autologous viruses were present in two animals ( Figures 1C and S3B ). One animal, rhesus macaque 5173, had potent plasma neutralization activity against the Tier-2 autologous 6-month CAP206 TF variant virus (Figures 1C and S3B) .
Neutralization of the 6-month virus emerged in 5173 plasma 2 weeks after the second immunization and was boosted by repetitive immunization and persisted throughout the remainder of the immunization regimen ( Figure 1D ). Plasma neutralization responses waned 20 months after the last immunization (data not shown). Thus, immunization with CAP206 Envs effectively elicited potent Tier-1 heterologous virus neutralization in all six animals and low levels of Tier-2 nAbs in two of them; in one animal, it rapidly induced an early and robust neutralization response to an autologous Tier-2 virus.
Immunization-Induced Neutralization Mimics Early Autologous CAP206 Plasma Neutralization Response Autologous Tier-2 neutralization in macaque 5173 was specific for the CAP206 6-month virus. Env sequences that were isolated from later time points post-infection from CAP206 contained numerous mutations that were candidate sites of immune pressure. Two of the very first observed Env sequence changes retained in the 6-month Env were in the V1/V2 and V5 regions ( Figure 2A ).
Closer inspection of the V5 sequences revealed extensive diversity in this region among longitudinal CAP206 Envs. Specifically, the 6-month Env had a five-amino-acid deletion and lacked a predicted glycosylation site at position 463 ( Figure 2B ). To determine whether 5173 neutralization of the 6-month CAP206 virus targeted V5, we engineered a mutation in the 6-month virus that introduced a glycosylation site at position 463 (S463N). We found persistent plasma neutralization of the wild-type 6-month virus for samples across the full immunization period but no neutralization of the glycosylation site variant ( Figure 2C ).
To examine the role of mutations in the V5 loop in early autologous escape of the infecting virus in CAP206, we tested CAP206 plasma isolated post-infection for the ability to neutralize the autologous 2-month and 12-month viral isolate. Early plasma samples exclusively neutralized the 2-month virus, and only later plasma samples acquired neutralization activity for the 12-month virus ( Figure 2D ). When we reverted the 12-month V5 region back to the 2-month sequence, the chimeric virus became sensitive to neutralization by early CAP206 plasma time points. Reverting mutations in the V1V2 in the 12-month back to the 2-month did not have any effect on early neutralization. Thus, the V5 loop was a target for autologous nAbs in CAP206 after infection and a V5-dependent autologous nAb response was elicited in a rhesus macaque by immunization with a CAP206 TF variant.
Immunization Elicited CD4bs Autologous nAbs
We isolated single Env-specific memory B cells from macaque 5173 PBMC using tetramers of the neutralization-sensitive CAP206 6-month Env as well as the neutralization-resistant CAP206 30-month Env. Memory cells (CD20 + and CD27 + ) that bound the 6-month, but not the 30-month, Env were sorted into individual wells of a 96-well plate ( Figure 3A) . The frequency of 6-month Env-specific memory B cells was 0.07% ( Figure 3A ). Single-cell PCR amplification and transient expression of immunoglobulin (Ig) genes of the sorted memory B cells identified two mAbs (DH427 and DH428) that specifically bound the CAP206 6-month Env in ELISA ( Figure 3B ). As expected from their sensitivity to changes at position 463, DH427 and DH428 competed for binding of soluble CD4 to CAP206 6-month Env ( Figure 3C ). Sequences of the heavy-and light-chain Ig genes showed that DH427 and DH428 are two members of the same B cell clonal lineage, which used the rhesus orthologs of the human V H 3-23 and V l 2-11 genes ( Figures 3D and S4) . Members of the DH427 lineage have short HCDR3s (10 aas); the variable heavy regions were mutated 4.5% in DH427 and 2.4% in DH428 ( Figure 3D ).
DH427 CD4bs
Antibody Lineage Neutralized the Tier-2 CAP206 6-Month Virus DH427 and DH428 neutralized the 6-month virus but did not neutralize any of the other autologous or heterologous viruses tested ( Figures 4A and S5) . Moreover, DH427 and DH428 did not neutralize the CAP206 6-month virus with an N463 mutation, recapitulating the pattern of neutralization observed in the 5173 plasma ( Figure 4A ).
The CAP206 6-month Env lacked a glycosylation site in V5; introduction of a glycosylation site in V5 of the CAP206 6-month Env eliminated neutralization by both 5173 plasma and DH427 lineage antibodies. The CAP206 TF Env also lacked a glycosylation site in V5, but the loop was five amino acid residues longer ( Figure 4B ). This virus resisted neutralization by DH427 and DH428; deletion of the five residues in V5 of the CAP206 TF virus to match the 6-month virus made it sensitive to both antibodies ( Figure 4C ). Thus, both the presence of glycosylation sites and the length of the V5 loop restricted CAP206 virus neutralization by DH427 and DH428.
Maturation of the DH427 Clonal Lineage
For an analysis of the evolution of the DH427 antibody lineage, we inferred the intermediate (I1) and the unmutated common ancestor antibodies of DH427 and DH428. The I1 and mature antibodies specifically and exclusively bound the CAP206 6-month Env, but there was no detectable binding of this particular unmutated common ancestor candidate antibody to any of the recombinant CAP206 Envs (Figures 5A and S6) . We showed that light-chain mutations between the unmutated common ancestor and I1 determined the difference in DH427/DH428 binding by pairing the unmutated common ancestor heavy chain with the I1 light chain and vice versa. Only the former had detectable affinity ( Figure 5B ). Failure of the inferred DH427 unmutated common ancestor to bind the immunogen led us to consider whether one or more of the amino acid residues considered to have come from somatic hypermutation (SHM) might instead be germline encoded in an as yet undiscovered rhesus macaque V l allelic variant, leading to an incorrect inference for the unmutated common ancestor.
We examined the germline IGLV2-F sequence in macaque 5173 by targeted genomic amplification and sequencing of extracted genomic DNA ( Figure S7 ). Sequencing of individual colonies detected an IGLV2-F allele (IGLV2-F*02) that shared three of the four residues that we had considered mutated in I1 ( Figure 5C ). We then sequenced the IGLV2-F allele in the five remaining animals in the immunization study and found IGLV2-F*02 in the genomic DNA of all five ( Figure S6C ). From these results, we designed a new unmutated common ancestor (UCA2) by incorporating the new germline light-chain allele. We found that inferred UCA2 bound the 6-month Env, indicating that UCA2 was the authentic initiator of the DH427/DH428 B cell lineage ( Figure 5D ).
The UCA2 antibody did not neutralize the 6-month virus, but both DH471 I1 and the chimeric (unmutated common ancestor V H : I1V L ) antibody did neutralize this virus (Figure 5E ). These results indicated that autologous neutralization activity required a specific sequence of light-chain affinity maturation.
DH427 Unmutated Common Ancestor Reacts with Host Protein FAM21C
Two macaques (5160 and 5184) had weak autologous nAb responses, one (5173) had a robust autologous nAb response, and three (5165, 5167, and 5183) had no autologous nAb response, yet all had received the same vaccine immunogen. This variability in the response suggested that host factors limited high levels of responses in the other five animals. To examine the role of cross-reactivity with host antigens for the development of Tier-2 nAbs, we tested each immunized macaque's plasma pre-and post-immunization for reactivity to common auto-antigens recognized by individuals with autoimmune disease ( Figure S7D ). We did not detect significant antibody polyreactivity in plasma for any of the auto-antigens tested.
Next, we tested the DH427 lineage for reactivity with the same auto-antigens and did not detect reactivity ( Figure S7E ). We then tested DH427 and the DH427 unmutated common ancestor antibodies for reactivity to >9,400 human proteins on a microarray ( Figure 5F ). We found that neither DH427 nor the unmutated common ancestor were polyreactive, but the unmutated common ancestor did react strongly with a single host protein Family of Sequence Similarity 21, Member C (FAM21C; Figure 5F ; Table S1 ). FAM21C is a member of the WASH complex that is involved in intracellular trafficking (Gomez and Billadeau, 2009) . These data raise the hypothesis that reactivity with auto-antigens may have blocked the initial maturation and/or expansion of DH427-like lineages in the other five macaques while having the correct germline V L allele. See also Figure S4 .
Structure of DH427 in Complex with HIV-1 gp120
The DH427/DH428 vaccine-induced lineage blocked CD4 binding and neutralized an autologous Tier-2 virus, but its genetic characteristics differed from those of most CD4bs nAbs. We crystallized and determined at 6.6 Å resolution the structure of the DH427 Fab in complex with a recombinant variant of the ZM1766.66 gp120 that had the CAP206 6-month V5-loop sequence. We also determined the structures of the DH427 and DH428 Fabs at 2.66 Å and 2.32 Å resolution, respectively (Table S2) . The DH427 Fab associates with HIV gp120 along an outer rim of the CD4-binding surface. CDRH2 and CDRH3 contact the V5 loop, and CDRL1 and CDRL3 contact loop E ( Figure 6A ). The limited resolution did not allow detailed description of side-chain interactions. We superposed onto the gp120 core domain from our complex the structure of the gp120 core domain bound with soluble CD4. The bulk of the Fab was large enough to block CD4 binding, even though their overlapping footprints differed substantially ( Figure 6B ). In contrast, the CD4bs bnAb VRC01 contacts conserved residues in the V5 loop and has more contacts in the CD4bs than DH427, allowing for more-effective CD4 blocking and broad antigen recognition ( Figure 6B ). Mutability of V5, at the core of their contact, and a very frequently found glycosylation site at position 355 on loop E clearly accounted for the restricted breadth of DH427 and DH428. For example, the glycan at position 463 would project directly into the face of the antibody ( Figure 6C ). Thus, further affinity maturation would be unlikely to generate much-greater neutralization breadth.
Superposition of the gp120 outer domain from its complex with DH427 onto the homologous domain in the BG505 SOSIP gp140 structure shows that the Fab would project laterally from the periphery of the trimer ( Figure 6D ). DH427 is in almost the same orientation as the CD4bs bnAb VRC01 but displaced outward by about 25 Å . This angle is also distinct from the prototypical Tier-1-neutralizing CD4bs mAb F105, which projects in a more-axial direction, making it prone to steric hindrance on the ''closed'' trimers of Tier-2 viruses ( Figure 6D ).
DISCUSSION
Recent studies show that bnAb lineages can evolve out of autologous nAb lineages present early in HIV-1 infection (Doria-Rose et al., 2014; Liao et al., 2013a; Wibmer et al., 2013) . All HIV-1-infected individuals produce autologous Tier-2 nAbs months after transmission, but not all HIV-infected individuals go on to make bnAbs (Bar et al., 2012; Doria-Rose et al., 2010; Gray et al., 2009b; Kwong et al., 2013; Richman et al., 2003; Wei et al., 2003) . Thus, eliciting strain-specific nAbs that target neutralization-resistant Tier-2 viruses can be a first step to develop bnAbs during vaccination. CAP206 is an HIV-infected individual that produced bnAbs targeting the MPER, but we found that the V5 loop was a target for autologous nAbs early after infection in CAP206. Thus, in CAP206, the autologous nAb response was unrelated to the bnAb response. Our finding that, after only two immunizations with a swarm of CAP206 Envs, the CAP206 6-month variant of the TF Env induced in one of six rhesus macaques potent autologous Tier-2 nAbs that targeted a similar nAb epitope observed in CAP206 shows that vaccination with gp140 oligomers can, in principle, also produce such antibodies. However, that only three macaques had autologous nAbs, and only one with high titers, contrasts with HIV infection, in which virtually all HIV-infected individuals make autologous nAbs. These studies raise several important issues for HIV vaccine development.
First, our structural studies of DH427 CD4bs autologous nAb demonstrated that DH427 neutralization was restricted to the autologous virus because antibody recognition centers on the V5 loop. Moreover, the mode of V5 contact prevented full engagement of the CD4bs and explains why this lineage is unlikely to achieve bnAb breadth with further affinity maturation.
Second, it is a conundrum that all HIV-infected individuals make autologous nAbs and up to 50% make some level of bnAbs, whereas no humans vaccinated with Envs have to date made either autologous nAbs or bnAbs. All the macaques in the group studied had the IGLV2-F germline allelic variant, and thus, all had the required V L repertoire to respond to Env immunization. One hypothesis is that there may be host control mechanisms for autologous nAbs in both macaques and humans and that the responding macaque (5173) was permissive for release of antibodies that can recognize a closed or Tier-2 envelope. There was no reactivity with auto-antigens common in autoimmune disease by the plasma or DH427 lineage antibodies, but the DH427 unmutated common ancestor antibody did react with host protein FAM21C. This reactivity may have limited expansion of this lineage in the other animals.
Broad neutralization appears only after years of persistent infection, in part because breadth requires high levels of SHM, even for those antibodies with relatively invariant Env contacts Kwong and Mascola, 2012; Scheid et al., 2009 Scheid et al., , 2011 . Driving high SHM by vaccination is particularly difficult, because many highly mutated antibodies are disfavored by the host immune system (Haynes and Verkoczy, 2014) . DH427 lineage antibodies required SHM for neutralization, but they were less than 5% mutated and were induced rapidly after only two immunizations. Thus, the DH427 lineage achieved potent Tier-2 autologous neutralization with minimal SHM.
Finally, HIV Env shifts from a ''closed'' to an ''open'' conformation when CD4 binds (Liu et al., 2008) . In that transition, it exposes epitopes concealed in the closed state. Any particular Env is in equilibrium between closed and open (and probably one or more intermediate) states (Julien et al., 2013; Pugach et al., 2015) . The key structural correlate of the distinction between Tier-1 and Tier-2 is whether this equilibrium is strongly on the side of the closed conformation (Tier-2, primarily bnAb site accessible) or more frequently toward the open conformation (strain-specific and non-neutralizing sites accessible). A recent study demonstrated that a stabilized recombinant native-like closed trimer Env (BG505 SOSIP.664) elicited nAbs to the sequence-matched Tier-2 virus in rabbits and in three of four macaques (Sanders et al., 2015) . In the Sanders et al. study in macaques, the titers of autologous nAbs ranged from 32 to 168, similar to the titers observed in an earlier study by and in the present study .The immunogen used here was a trimeric Env, but not a variant (such as BG505 SOSIP.664) locked into a closed state by intentional modification. Nonetheless, it elicited potent autologous nAbs, and in at least the one lineage we have studied, those nAbs recognized a site accessible of the surface of a Tier-2 virus and thus, by inference, on the surface of a closed trimer. Although the DH427 nAb Env epitope appears to be too variable, both in the length of the loops and in their potential for glycosylation, to be a target for bnAbs, its proximity to the CD4bs and its dependence on similar conformational parameters suggest that related vaccine immunogens could also induce the germline precursors of CD4bs bnAbs. Indeed, whereas most Env immunogens fail to engage germline-reverted CD4bs-directed bnAbs, including Table S2 .
ing B cell responses to the CD4bs. Moreover, modifying the CAP206 Env to have a more-closed structure by SOSIP modification may also increase immunogenicity. Such structural considerations coupled with understanding host control of induction of nAbs should lead to design of strategies for inducing autologous nAbs to Tier-2 HIV with greater heterologous neutralization breadth (Liao et al., 2013a) .
EXPERIMENTAL PROCEDURES Donor Subject
CAP206 is an HIV-1 subtype C chronically infected individual used for this study. This participant was part of the CAPRISA 002 Acute infection cohort whose antibody neutralization profile has been studied since the point of seroconversion (Gray et al., 2007 (Gray et al., , 2009b . This study was approved by the IRBs of the Universities of KwaZulu Natal and Witwatersrand in South Africa and Duke University. Written informed consent was obtained from all study participants.
Design and Production of Recombinant gp140 Proteins Derived from CAP206
The cloning and sequencing of env sequences was performed as described previously from longitudinal samples from CAP206 (L.M., unpublished data; Gray et al., 2007; Keele et al., 2008) . The single TF and six mutant clones from later time points (CAP206 TF, 2 months, 6 months, 12 months, 21 months, 24 months, and 30 months) were selected for production as soluble gp140 trimeric immunogens. The recombinant Envs were expressed in 293T cells and purified using lectin and size-exclusion chromatography as described previously (Liao et al., 2013b) .
Immunization of Rhesus Macaques
Six rhesus macaques each received seven intramuscular immunizations at 6-week intervals with seven CAP206 Env immunogens (100 mg total) in MF59 adjuvant (Novartis). Blood samples were collected 2 weeks after each immunization. All rhesus macaques were housed at Bioqual. All rhesus macaques were maintained in accordance with the Association for Assessment and Accreditation of Laboratory Animals with the approval of the Animal Care and Use Committees of the NIH and Harvard Medical School. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 2011 edition.
Antibody Isolation CAP206 6-month gp140 and CAP206 30-month gp140 proteins were fluorescently labeled with AF647 and BV421 (Invitrogen), respectively. Peripheral blood mononuclear cells (PBMCs) from rhesus monkey 5173 at week 38 were stained with fluorescently labeled antibodies for cell surface markers and both CAP206 Envs. Memory B cells that were stained positive for the CAP206 6-month Env and not the CAP206 30-month Env were sorted into single wells of 96-well PCR plates containing RT-PCR buffer as previously described (Wiehe et al., 2014) . Antibody variable heavy and variable light genes were amplified using nested PCR and purified and sequenced as described previously (Wiehe et al., 2014) . VDJ arrangements, clonal relatedness, and identification of the intermediate and unmutated common ancestor were inferred using previously described computational methods (Kepler, 2013; Munshaw and Kepler, 2010) .
Sequencing of Germline Variable Region
Genomic DNA was isolated from all six animals from PBMCs at 2 weeks after the first immunization (QIAmp DNA Blood mini kit; QIAGEN). IGLV2-F sequences were amplified using two independent primer sets. To ensure amplification of non-rearranged variable sequences, both primer sets reverse primers aligned to sequences present in the non-coding genomic DNA downstream the V-recombination site. The forward primer for set 1 resided in the IGV2-F leader sequence and upstream of the leader in set 2. The PCR fragments were cloned into a pcDNA2.1 (TOPO-TA kit; Life Technologies) and transformed into bacteria for sequencing of individual colonies.
Expression of Recombinant Antibodies
Transient small-scale expression of antibodies was achieved by assembling VH, VK, or VL sequences with linear cassettes that contain the CMV promoter, respective Ig constant region, and poly A signal sequence using overlapping PCR and transfection into 293T cells as described previously (Liao et al., 2009) . Supernatants were directly used to screen for binding of Env antigens in ELISA.
For production of purified recombinant mAbs, the VH and VL genes from DH427 lineage antibodies were cloned into expression vectors and expressed and purified as described previously . Site-directed mutagenesis of antibody genes was performed using the Quikchange II lightening multisite-directed mutagenesis kit (Agilent).
ELISA binding of transiently transfected supernatants and purified recombinant mAbs was performed as described previously .
Surface Plasmon Resonance
Surface plasmon resonance assays were performed on a BIAcore 4000 instrument, and data analysis was performed with BIAevaluation 4.1 software (BIAcore). Anti-gp120 mAbs or sCD4 in 10 mM Na-acetate buffer (pH 4.5) were directly immobilized to CM5 sensor chips using a standard amine coupling protocol for protein immobilization. Purified CAP206 Env glycoproteins were flowed over CM5 sensor chips at concentrations of 2-100 mg/ml. Binding of CAP206 envelope proteins was monitored in real time at 25 C with a continuous flow of PBS (150 mM NaCl, 0.005% surfactant P20 [pH 7.4]) at 10-30 ml/min Gao et al., 2014) .
Neutralization Assays
Neutralization activities of animal plasma and purified antibodies were determined by the TZM-bl cell-based neutralization assay (Sarzotti-Kelsoe et al., 2014) . Tier phenotyping of the pseudoviruses was assayed by sensitivity to a pool of HIV-infected serum as described previously (Seaman et al., 2010) .
Antibody Reactivity with Host Proteins
The polyreactivity of the DH427 lineage was assayed in the AtheNA multi-lyte system (Zeus Scientific). The rhesus mAbs were also tested for reactivity with human host cellular antigens using ProtoArray 5 microchip (Life Technologies) compared to a rhesus isotype-matched control antibody as described previously (Yang et al., 2013) .
Expression and Purification of Proteins for Crystallization
The heavy-and light-chain variable and constant domains of the DH427 and DH428 Fabs were cloned into the pVRC-8400 expression vector using Not1 and Nhe1 restriction sites and the tissue plasminogen activator signal sequence. The C terminus of the heavy-chain constructs contained a noncleavable 63 histidine tag. Fabs were expressed and purified as described previously (Fera et al., 2014) . The codon-optimized synthetic construct of the ZM176.66 HIV-1 subtype C gp120 containing aa 41-492 (HXB2 numbering) DV123 (core) was produced by GenScript with an N-terminal 63-histidine tag and inserted into the pVRC-8400 expression vector as described for Fabs. The V5 loop of this gp120 core was mutated to that of the CAP206 6-month envelope by site-directed mutagenesis using manufacturer's protocols (Stratagene) and expressed in 293S GnTi-suspension adapted cells using linear PEI. After 5 days of expression, supernatants were clarified by centrifugation and passed over galanthus nivalis lectin resin pre-equilibrated with 13 PBS. Bound protein was washed with 13 PBS and eluted with 13 PBS and 500 mM methyl a-D mannopyranoside. The glycoprotein was then deglycosylated overnight at 37 C with Endo H in a buffer of 50 mM sodium acetate (pH 6.0), 5 mM EDTA, 500 mM NaCl, 1 mg/ml leupeptin, and 1 mg/ml aprotonin. Deglycosylated gp120 core was then purified by gel filtration chromatography in buffer B (2.5 mM Tris [pH 7.5], 350 mM NaCl, and 0.02% sodium azide) using a superdex 200 analytical column (GE Healthcare). To make the complex for co-crystallization, DH427 and the ZM176.66 gp120 mutant were mixed in a 1.2:1 molar ratio and incubated for at least 1 hr before passing over a superdex 200 preparatory column (GE Healthcare) in buffer B. Fractions corresponding to the complex were combined and concentrated to 10 mg/ml for co-crystallization trials.
Crystallization, Structure Determination, and Refinement All His-tagged Fabs were crystallized at 15 mg/ml, and the DH427/ZM176.66 mutant gp120 core complex was crystallized at 10 mg/ml. Crystals were grown in 96-well format using hanging drop vapor diffusion and appeared after 24-48 hr at 20 C. DH427 crystals were obtained in a condition of 20% polyethylene glycol (PEG) 2K monomethyl ether (MME), 100 mM sodium citrate (pH 4.0), and 100 mM NaCl; and DH428 crystals were grown over a reservoir of 40% PEG 400 and 100 mM sodium acetate (pH 5.0). Initial crystals of DH427/gp120 core complex were obtained in a condition of 1.5 M ammonium sulfate and 100 mM Tris (pH 8.0) and were optimized to 24-well format to obtain larger crystals. All crystals were harvested and cryoprotected by the addition of 20%-25% glycerol to the reservoir solution and then flash cooled in liquid nitrogen. Crystals of complex were cryoprotected with a series of different cryoprotectants including 15%-30% glycerol, 15%-30% ethylene glycol, and 1 or 2 M sodium malonate; however, the best diffraction was obtained with 20%-30% glycerol or ethylene glycol as the cryoprotectant. Diffraction data were obtained at 100 K from beam lines 24-ID-C and 24-ID-E at the Advanced Photon Source using a single wavelength. Data sets from individual crystals (two crystals for DH427 and one crystal for DH428) were processed with HKL2000 (Otwinowski and Minor, 1997) and XDS (Kabsch, 2010) for DH427 and DH428, respectively. Molecular replacement calculations for the free Fabs were carried out with PHASER (McCoy, 2007) , using I3.2 from the CH103 lineage (PDB ID 4QHL) as the starting model. The I3.2 model was separated into its variable and constant domains for the DH427 and DH428 Fab structure determinations. Crystals of the DH427 and DH428 Fabs had four and one molecules per asymmetric unit, respectively. For both Fabs, subsequent refinement steps were carried out with PHENIX (Adams et al., 2010) , and all model modifications were carried out with Coot (Emsley and Cowtan, 2004 ). During refinement, maps were generated from combinations of positional, group B-factor, and TLS (translation/ libration/ screw) refinement algorithms. Secondary-structure restraints were included at all stages for all Fabs; noncrystallographic symmetry restraints were applied to the DH427 Fab throughout refinement.
Data from multiple crystals of the DH427/gp120 core complex were processed using HKL2000 (Otwinowski and Minor, 1997) , and molecular replacement calculations were carried out with PHASER (McCoy, 2007) , using the refined DH427 coordinates and gp120 core from the VRC01/gp120 complex (PDB ID 4LST) as the starting models. DH427 was separated into its variable and constant domains for structure determinations. There were two molecules per asymmetric unit. The resulting electron density map for the complex was further improved by solvent flattening, histogram matching, and noncrystallographic symmetry averaging using the program Parrot (Winn et al., 2011) . Phase combination was disabled in these calculations. After density modification, rigid-body refinement was performed using Refmac in Coot.
Structure validations were performed periodically during refinement using the MolProbity server (Davis et al., 2007) . The final refinement statistics are summarized in Table S1 .
Protein Structure Analysis and Graphical Representations
The core domain of the chimeric ZM176.66 gp120 core mutant designed in our study was superposed on other gp120 cores from the PDB by least-squares fitting in Coot. All graphical representations with protein crystal structures were made using PyMol.
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